// App-Quantinova.ai

2979 : Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC

Researchers

Presenter

  • Nayel Khan

Principal Investigators

  • Kara S. Davis

  • Neal Godse

  • Carolyn Kemp

  • Sucheta Kulkarni

  • Diego Alvarado

  • Theresa LaVallee

  • Jennifer R. Grandis

  • Umamaheswar Duvvuri

Medical Centers

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Kolltan Pharmaceuticals, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Erb-B2 Receptor Tyrosine Kinase 3

Drug/Treatment

  • KTN3379

  • Alpelisib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved